Last reviewed · How we verify
Ziltivekimab B
Ziltivekimab B is an interleukin-1 beta (IL-1β) inhibitor.
Ziltivekimab B is an interleukin-1 beta (IL-1β) inhibitor. Used for Treatment of generalized pustular psoriasis.
At a glance
| Generic name | Ziltivekimab B |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | IL-1β inhibitor |
| Target | IL-1β |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 3 |
Mechanism of action
It works by binding to IL-1β and preventing its interaction with the IL-1 receptor, thereby reducing inflammation and modulating the immune response.
Approved indications
- Treatment of generalized pustular psoriasis
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
- A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab (PHASE1)
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ziltivekimab B CI brief — competitive landscape report
- Ziltivekimab B updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI